Veszprém Megyei Tüdőgyógyintézet 049/2 Hrsz_Investigational Site Number :3480004
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MEDGYASSZAY, Balázs
CARMEN-LC05, NCT04524689 / 2020-000035-50: Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Hourglass Apr 2022 - Dec 2022 : Data from CARMEN-LC05 trial in combination with pembrolizumab for PDL1+ advanced NSCLC
Terminated
2
57
Europe, US, RoW
SAR408701 (Tusamitamab ravtansine), Tusamitamab ravtansine, Pembrolizumab, Keytruda, Cisplatin, Carboplatin, Pemetrexed
Sanofi
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
03/24
12/24
VAJCS, Szilvia
CARMEN-LC05, NCT04524689 / 2020-000035-50: Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Hourglass Apr 2022 - Dec 2022 : Data from CARMEN-LC05 trial in combination with pembrolizumab for PDL1+ advanced NSCLC
Terminated
2
57
Europe, US, RoW
SAR408701 (Tusamitamab ravtansine), Tusamitamab ravtansine, Pembrolizumab, Keytruda, Cisplatin, Carboplatin, Pemetrexed
Sanofi
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
03/24
12/24
Gerlochová, Zuzana
CARMEN-LC05, NCT04524689 / 2020-000035-50: Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Hourglass Apr 2022 - Dec 2022 : Data from CARMEN-LC05 trial in combination with pembrolizumab for PDL1+ advanced NSCLC
Terminated
2
57
Europe, US, RoW
SAR408701 (Tusamitamab ravtansine), Tusamitamab ravtansine, Pembrolizumab, Keytruda, Cisplatin, Carboplatin, Pemetrexed
Sanofi
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
03/24
12/24

Download Options